These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
44. In vivo evaluation of 99mTc/188Re-labeled linear alpha-melanocyte stimulating hormone analogs for specific melanoma targeting. Chen J; Giblin MF; Wang N; Jurisson SS; Quinn TP Nucl Med Biol; 1999 Aug; 26(6):687-93. PubMed ID: 10587108 [TBL] [Abstract][Full Text] [Related]
45. Three-dimensional molecular models of the hMC1R melanocortin receptor: complexes with melanotropin peptide agonists. Haskell-Luevano C; Sawyer TK; Trumpp-Kallmeyer S; Bikker JA; Humblet C; Gantz I; Hruby VJ Drug Des Discov; 1996 Dec; 14(3):197-211. PubMed ID: 9017363 [TBL] [Abstract][Full Text] [Related]
46. alpha-MSH receptor autoradiography on mouse and human melanoma tissue sections and biopsies. Bagutti C; Oestreicher M; Siegrist W; Oberholzer M; Eberle AN J Recept Signal Transduct Res; 1995; 15(1-4):427-42. PubMed ID: 8903955 [TBL] [Abstract][Full Text] [Related]
47. Alpha-melanocyte-stimulating hormone exhibits target cell selectivity in its capacity to affect interleukin 1-inducible responses in vivo and in vitro. Daynes RA; Robertson BA; Cho BH; Burnham DK; Newton R J Immunol; 1987 Jul; 139(1):103-9. PubMed ID: 3495595 [TBL] [Abstract][Full Text] [Related]
52. [Detection of binding activity and biologic effect of a novel alpha-melanocyte-stimulating hormone analogue]. Ying Y; Lan XP; Tian YP Yao Xue Xue Bao; 2007 Mar; 42(3):269-73. PubMed ID: 17520825 [TBL] [Abstract][Full Text] [Related]
53. Evidence for alternate points of attachment for alpha-MSH and its stereoisomer [Nle4, D-Phe7]-alpha-MSH at the melanocortin-1 receptor. Frändberg PA; Muceniece R; Prusis P; Wikberg J; Chhajlani V Biochem Biophys Res Commun; 1994 Aug; 202(3):1266-71. PubMed ID: 8060302 [TBL] [Abstract][Full Text] [Related]
54. Cholecystokinin-B/gastrin receptor binding peptides: preclinical development and evaluation of their diagnostic and therapeutic potential. Behr TM; Béhé M; Angerstein C; Gratz S; Mach R; Hagemann L; Jenner N; Stiehler M; Frank-Raue K; Raue F; Becker W Clin Cancer Res; 1999 Oct; 5(10 Suppl):3124s-3138s. PubMed ID: 10541353 [TBL] [Abstract][Full Text] [Related]
55. Radioiodination of internalizing monoclonal antibodies using N-succinimidyl 5-iodo-3-pyridinecarboxylate. Reist CJ; Garg PK; Alston KL; Bigner DD; Zalutsky MR Cancer Res; 1996 Nov; 56(21):4970-7. PubMed ID: 8895752 [TBL] [Abstract][Full Text] [Related]
57. Preparation of N-succinimidyl 3-[*I]iodobenzoate: an agent for the indirect radioiodination of proteins. Vaidyanathan G; Zalutsky MR Nat Protoc; 2006; 1(2):707-13. PubMed ID: 17406300 [TBL] [Abstract][Full Text] [Related]
58. Synthesis and biological evaluation of the superagonist [N alpha-chlorotriazinylaminofluorescein-Ser1,Nle4,D-Phe7]-al pha-MSH. Chaturvedi DN; Hruby VJ; Castrucci AM; Kreutzfeld KL; Hadley ME J Pharm Sci; 1985 Mar; 74(3):237-40. PubMed ID: 2989482 [TBL] [Abstract][Full Text] [Related]
59. An improved imaging agent for malignant melanoma, based on [Nle4,D-Phe7]alpha-melanocyte stimulating hormone. Bard DR Nucl Med Commun; 1995 Oct; 16(10):860-6. PubMed ID: 8570117 [TBL] [Abstract][Full Text] [Related]
60. Antagonist and agonist activities of the mouse agouti protein fragment (91-131) at the melanocortin-1 receptor. Eberle AN; Bódi J; Orosz G; Süli-Vargha H; Jäggin V; Zumsteg U J Recept Signal Transduct Res; 2001 Feb; 21(1):25-45. PubMed ID: 11693171 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]